What this means
This is a plan for a study that has not started enrolling people yet. It will look at whether a skin treatment is safe and whether it works, but no results have been reported.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 40–65 · Up to 8 people, with 6 expected to finish the study
- Where
- Not listed
The science
- Registered title
- PIEZO-101 First-in-Human Safety and Proof-of-Concept Study
- Trial ID
- NCT07671027 ↗
- Phase
- EARLY PHASE 1
- Study type
- interventional
- Conditions
- Skin Aging, Wrinkles in Decolletage, Wrinkles in Left Knee, Left Knee Skin Laxity, Décolleté Wrinkles
- What is tested
- PIEZO-101, Piezopen, Sterile Saline (0.9% NaCl)
- Sponsor
- Piezo Therapeutics, Inc.
- Ages
- 40 Years to 65 Years
- Dates
- First posted Jun 26, 2026 · updated Jun 26, 2026
Registry summary
The aim of this first-in-human clinical study is to explore the safety, tolerability, pharmacodynamics, and exploratory efficacy of PIEZO-101, an investigational plasmid DNA biostimulator that aims to restore expression of key proteins in the skin for extracellular matrix rejuvenation. PIEZO-101 is administered using an intradermal injection followed by localized electroporation using the investigational device Piezopen. This clinical trial will study safety and tolerability, pharmacodynamics using biopsies from the left knee, and exploratory efficacy using photography on the décolleté. Up to 8 participants may be enrolled to ensure 6 evaluable participants complete the study.